medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2017, Number 08

<< Back Next >>

Ginecol Obstet Mex 2017; 85 (08)

Evidence in progesterone prescription

Buitrón-García FR, Bailón-Uriza R, Santoyo-Haro S, Díaz-Sánchez V

Language: Spanish
References: 41
Page: 489-497
PDF size: 222.11 Kb.


ABSTRACT

Background: Progesterone is a steroid hormone involved in ovulation, implantation, pregnancy and regulation of uterine function during the menstrual cycle and other organs such as the mammary gland. Because of its mechanism of action, progesterone is indicated in different gynecological and obstetric conditions: premenstrual syndrome, threatened abortion, preterm birth, dysfunctional uterine bleeding and mastalgia related to the menstrual cycle.
Objetive: To evaluate the safety and efficacy of progesterone in patients with: premenstrual syndrome, threatened abortion, preterm birth, dysfunctional uterine bleeding, mastalgia and hormone therapy in menopause.
Material and Methods: Systematic review of scientific evidence about different indications of progesterone.
Results: We found 92 articles from wich 41 were selected for review.
Conclusions: The clinical evidence evaluated on different indications of progesterone demonstrates advantages in efficacy and safety in different regimens.


REFERENCES

  1. Al-Asmakh. Reproductive functions of progesterone. Middle East Fertility Society 2007;12(3):147-152.

  2. Orizaba-Chávez B, Albo-Jasso G, Ocharán-Hernández M. Farmacocinética de la progesterona. Rev Hosp Jua Mex 2013; 80(1):59-66.

  3. Wieser F. Progesterone increases the number of Langerhans cells in human vaginal epithelium. Fertility and Sterility 2001;75(6):1234-1235.

  4. Marx S, Wentz M, MacKay L, et al. Effects of progesterone on iNOS, COX-2, and collagen expression in the cervix. Journal of Histochemistry & Cytochemistry 2006;54(6):623-639.

  5. Bargallo M, Domínguez L, Licata G, et al. Vascular effects of progesterone. Role of celular calcium regulation. Hypertension 2001;37:142-147.

  6. Szmuilowiez E, Adler G, Williams J, et al. Relationship between Aldosterone and Progesterone in the human menstrual cycle. The Journal of Clinical Endocrinology & Metabolism 2006;91(10):3981-3987.

  7. Subhash C, Shashi K. Diagnosis and treatment of premenstrual dysphoric disorder. American Academy of Family Physicians 2002;66(7):1239-1248.

  8. Ford O, Lethaby A, Roberts H, Mol BWJ. Progesterone for premenstrual syndrome. Cochrane Database System Rev 2009;2:CD003415. DOI: 10.1002/14651858.CD003415. pub3.

  9. Magill PJ. Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. Progesterone Study Group. Br J Gen Pract 1995;45(400):589-93.

  10. Vanselow W, Dennerstein L, Greenwood KM. Effect of progesterone and its 5 alpha and 5 beta metabolites on symptoms of premenstrual syndrome according to route of administration. J Psychosom Obstet Gynaecol 1996;17(1):29-38.

  11. Paragiano A, Bulleti C, Pace MC. Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy. Ann N Y Acad Sci 2004;1034:200-210.

  12. Wahabi HA, Abed Althagafi NF, Elawad M. Progestogen for treating threatened miscarriage. Cochrane Database System Rev 2007;3:CD005943. DOI: 10.1002/14651858. CD005943.pub2.

  13. Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database System Rev 2008;2: CD003511. DOI: 10.1002/14651858. CD003511.pub2.

  14. Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database System Rev 2013;10:CD003511. DOI: 10.1002/14651858.CD003511.pub3.

  15. Conde-Agudelo, Romero R, Nicolaides K. Vaginal progesterone vs cervical cerclaje for the prevention of preterm birth in women with a sonographic short cervix, previous preterm birth, and singleton gestation: a systematic review and indirect comparison metaanalysis. Am J Obstet Ginecol 2013;208:42.e1-18.

  16. Di Renzo GC, Cabero Roura L, Facchinetti F. Guidelines for the management of spontaneous preterm labor: identification of spontaneous preterm labor, diagnosis of preterm premature rupture of membranes, and preventive tools for preterm birth. J Matern-Fetal Neo M 2011;24(5):659-667.

  17. Roelens K, Robertfroid D, Ahmadzai N. Prevention of preterm birth in women at risk: select topics-Abstract. Good Clinical Practice (GPC); Brussels: Belgian Health Care Knowledge Centre (KCE). 2014. KCE Reports. D/2014/10.273/62

  18. Sánchez-Rodríguez O, Bello de Ita A. Parto pretérmino. Guía de práctica clínica. COMEGO 2015. 250-285.

  19. National Institute for Health and Care Excellence. Preterm labour and birth. NICE Guidelines 2015. 1-25 [Disponible en: https://www.nice.org.uk/guidance/NG25]

  20. Dodd JM, Flenady V, Cincotta R, Crowther CA. Prenatal administration of progesterone for preventing preterm birth. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD004947. DOI: 10.1002/14651858. CD004947.pub2.

  21. Fonseca EB, Bittar RE, Carvalho MHB. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: A randomized placebo-controlled doubleblind study. Am J Obstet Gynecol 2003;188:419-424.

  22. Fonseca EB, Celik E, Parra M. Progesterone and the risk of preterm birth among women with a short cérvix. NEJM 2007,357:462-9.

  23. Martinez de Tejada B, Karolinski A, Ocampo Mc, et al. Prevention of preterm delivery with vaginal progesterone in women with preterm labour (4P): randomised doubleblind pacebo-controlled trial. BJOG 2015;122(1):80-91.

  24. American College of Obstetricians and Gynecologists. Use of progesterone to reduce preterm birth. Committee Opinion No. 419. Washington, DC: American College of Obstetricians and Gynecologists; 2008.

  25. McNahara HC, Wood R, Chalmers J, et al. STOPPIT Baby follow-up –Study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. PLoS One 2015:10(4):e0122341.

  26. Norman JE, Marlow N, Messow CM. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicenter, randomized, double-blind trial. The lancet 2016. Disponible en: http://dx.doi.org/10.1016/S0140- 6736(16)00350-0).

  27. Rosolowichi V, Saettller E, Szuck B. Mastalgia. Clinical Practice Guideline (Num. 170). SOGC 2006;49-57.

  28. Nappi, C, Affinito P, DiCarlo C, Esposito G. Montemagno U. Double-blind controlled trial of progesterone vaginal cream treatment for cyclical mastodynia in women with benign breast disease. J Endocrinol Invest 1992;15:801-6.

  29. Euhus DM, Uyehara C. Influence of parental progesterone’s on the prevalence and severity of mastalgia in pre-menopausal women: a multi-institutional cross-sectional study. J Am Coll Surg 1997;84:596-604.

  30. Mainero-Ratchelous FE, López-Valle MA, Iturralde- Rosas P. Mastalgia. Guía de Práctica Clínica COMEGO 2015;101-115.

  31. Stanczyk FZ, Hapgood JP, Winer S, Mishell D. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions and clinical effects. Endocrine Rev 2013; 34: 171-208.

  32. Miles RA, Paulson RJ, Lobo RA, et al. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 1994;62:485-490.

  33. L’Hermite M, Simoncine T, Fuller S, et al. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas 2008;60:185-201.

  34. Khul H. Pharmacology of Progestogens. J Reproduktionsmed Endokrinol 2011;8(Special Issue 1):157-76.

  35. Vademecum PR [actualizado 2014]. Disponible en: http:// mx.prvademecum.com/producto.php?producto=2594

  36. The Royal Australian and New Zealand College of Obstetricians and Gynecologist (RANZCOG). Menopausal Hormone Therapy Advice. Australia: RANZCOG;2015.

  37. The 2012 Hormone Therapy Position Statement of the North American Menopause Society. Menopause 2012;19(3):257-271.

  38. The Society of Obstetricians and gynaecologist of Canada. (SOGC) Abnormal uterine bleeding in pre-menopausal women. 2013;FIGO, 2011.

  39. Derman SG, Rehnstrom J, Neuwirth RS. The long term effectiveness of hysteroscopic treatment of menorrhagia and leiomyomas. Obstet Gynecol 1991;77:591-594.

  40. Alanís-Fuentes J, Zacarías-Castillo R. Sangrado uterino anormal (y el endocrinólogo). Endocrinol Nutr 2005;13(1):39-46.

  41. Stacy R.A., Nelson A.L. A new progestogen-only medical therapy for outpatient management of acute, abnormal uterine bleeding: a pilot sudy. Am J Obstet Gynecol 2013;208:499.e1-5.




2020     |     www.medigraphic.com